Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.

Hoog M, Maldonado JM, Wangia-Dixon R, Halpern R, Buysman E, Gremel GW, Huang A, Konig M

Diabetes therapy : research, treatment and education of diabetes and related disorders1 Mar 2024

PMID38427164PMCIDPMC10951167DOI10.1007/s13300-024-01542-5PepBankPUB-38427164

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In Hispanic/Latino adults with diabetes, dulaglutide was linked to greater HbA1c reduction than basal insulin.
In plain wordsIn Hispanic/Latino adults with diabetes, dulaglutide was linked to greater HbA1c reduction than basal insulin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction
Study
n = 2,872
Comparator
Basal insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean change in HbA1c from baseline at 12 months
−1.4%
dulaglutide cohort (SD 1.88)
Mean change in HbA1c from baseline at 12 months
−0.92%
basal insulin cohort (SD 2.07)
Source sentences
Summary
Mean (SD) reduction in HbA1c from baseline to 12 month follow-up was greater in the dulaglutide cohort compared with the basal insulin cohort [-1.40% (1.88) versus -0.92% (2.07); p < 0.001].
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational study used administrative claims data from the Optum Research Database.
Summary · context
Hispanic/Latino adults with T2D were assigned to dulaglutide or basal insulin cohorts on the basis of pharmacy claims and were propensity-score matched on demographic and baseline characteristics.
Report a problemFND-3842716401
02HumanObservational studyOther
In Hispanic/Latino adults with diabetes, dulaglutide was linked to a lower proportion with at least one all-cause outpatient visit than basal insulin.
In plain wordsDulaglutide was linked to a lower proportion having at least one all-cause outpatient visit than basal insulin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAll-cause outpatient visits
Study
n = 2,872
Comparator
Basal insulin
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
The dulaglutide cohort had significantly lower proportions of patients with ≥ 1 all-cause and diabetes-related outpatient visits, emergency room visits, and inpatient stays compared with the basal insulin cohort (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational study used administrative claims data from the Optum Research Database.
Summary · context
Hispanic/Latino adults with T2D were assigned to dulaglutide or basal insulin cohorts on the basis of pharmacy claims and were propensity-score matched on demographic and baseline characteristics.
Report a problemFND-3842716402
03HumanObservational studyOther
In Hispanic/Latino adults with diabetes, dulaglutide was linked to a lower proportion with at least one diabetes-related outpatient visit than basal insulin.
In plain wordsDulaglutide was linked to a lower proportion having at least one diabetes-related outpatient visit than basal insulin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDiabetes-related outpatient visits
Study
n = 2,872
Comparator
Basal insulin
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
The dulaglutide cohort had significantly lower proportions of patients with ≥ 1 all-cause and diabetes-related outpatient visits, emergency room visits, and inpatient stays compared with the basal insulin cohort (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational study used administrative claims data from the Optum Research Database.
Summary · context
Hispanic/Latino adults with T2D were assigned to dulaglutide or basal insulin cohorts on the basis of pharmacy claims and were propensity-score matched on demographic and baseline characteristics.
Report a problemFND-3842716403
04HumanObservational studyOther
In Hispanic/Latino adults with diabetes, dulaglutide was linked to a lower proportion with at least one all-cause emergency room visit than basal insulin.
In plain wordsDulaglutide was linked to a lower proportion having at least one all-cause emergency room visit than basal insulin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAll-cause emergency room visits
Study
n = 2,872
Comparator
Basal insulin
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
The dulaglutide cohort had significantly lower proportions of patients with ≥ 1 all-cause and diabetes-related outpatient visits, emergency room visits, and inpatient stays compared with the basal insulin cohort (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational study used administrative claims data from the Optum Research Database.
Summary · context
Hispanic/Latino adults with T2D were assigned to dulaglutide or basal insulin cohorts on the basis of pharmacy claims and were propensity-score matched on demographic and baseline characteristics.
Report a problemFND-3842716404
05HumanObservational studyOther
In Hispanic/Latino adults with diabetes, dulaglutide was linked to a lower proportion with at least one diabetes-related emergency room visit than basal insulin.
In plain wordsDulaglutide was linked to a lower proportion having at least one diabetes-related emergency room visit than basal insulin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDiabetes-related emergency room visits
Study
n = 2,872
Comparator
Basal insulin
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
The dulaglutide cohort had significantly lower proportions of patients with ≥ 1 all-cause and diabetes-related outpatient visits, emergency room visits, and inpatient stays compared with the basal insulin cohort (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational study used administrative claims data from the Optum Research Database.
Summary · context
Hispanic/Latino adults with T2D were assigned to dulaglutide or basal insulin cohorts on the basis of pharmacy claims and were propensity-score matched on demographic and baseline characteristics.
Report a problemFND-3842716405
06HumanObservational studyOther
In Hispanic/Latino adults with diabetes, dulaglutide was linked to a lower proportion with at least one all-cause inpatient stay than basal insulin.
In plain wordsDulaglutide was linked to a lower proportion having at least one all-cause inpatient stay than basal insulin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAll-cause inpatient stays
Study
n = 2,872
Comparator
Basal insulin
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
The dulaglutide cohort had significantly lower proportions of patients with ≥ 1 all-cause and diabetes-related outpatient visits, emergency room visits, and inpatient stays compared with the basal insulin cohort (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational study used administrative claims data from the Optum Research Database.
Summary · context
Hispanic/Latino adults with T2D were assigned to dulaglutide or basal insulin cohorts on the basis of pharmacy claims and were propensity-score matched on demographic and baseline characteristics.
Report a problemFND-3842716406
07HumanObservational studyOther
In Hispanic/Latino adults with diabetes, dulaglutide was linked to a lower proportion with at least one diabetes-related inpatient stay than basal insulin.
In plain wordsDulaglutide was linked to a lower proportion having at least one diabetes-related inpatient stay than basal insulin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDiabetes-related inpatient stays
Study
n = 2,872
Comparator
Basal insulin
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
The dulaglutide cohort had significantly lower proportions of patients with ≥ 1 all-cause and diabetes-related outpatient visits, emergency room visits, and inpatient stays compared with the basal insulin cohort (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational study used administrative claims data from the Optum Research Database.
Summary · context
Hispanic/Latino adults with T2D were assigned to dulaglutide or basal insulin cohorts on the basis of pharmacy claims and were propensity-score matched on demographic and baseline characteristics.
Report a problemFND-3842716407
08HumanObservational studyOther
In Hispanic/Latino adults with diabetes, dulaglutide was linked to lower all-cause costs per HbA1c reduction than basal insulin.
In plain wordsIn Hispanic/Latino adults with diabetes, dulaglutide was linked to lower all-cause costs per HbA1c reduction than basal insulin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAll-cause costs per HbA1c reduction
Study
n = 2,872
Comparator
Basal insulin
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
All-cause total costs per 1% HbA1c reduction
13,768 USD
dulaglutide cohort
All-cause total costs per 1% HbA1c reduction
19,128 USD
basal insulin cohort
Source sentences
Summary
The dulaglutide cohort had significantly lower all-cause total costs per 1% HbA1c reduction than the basal insulin cohort ($13,768 versus $19,128; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational study used administrative claims data from the Optum Research Database.
Summary · context
Hispanic/Latino adults with T2D were assigned to dulaglutide or basal insulin cohorts on the basis of pharmacy claims and were propensity-score matched on demographic and baseline characteristics.
Report a problemFND-3842716408
09HumanObservational studyOther
In Hispanic/Latino adults with diabetes, diabetes-related costs per HbA1c reduction did not differ significantly between dulaglutide and basal insulin.
In plain wordsIn Hispanic/Latino adults with diabetes, diabetes-related costs per HbA1c reduction did not differ significantly between dulaglutide and basal insulin.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeDiabetes-related costs per HbA1c reduction
Study
n = 2,872
Comparator
Basal insulin
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Diabetes-related costs per 1% HbA1c reduction
9737 USD
dulaglutide cohort
Diabetes-related costs per 1% HbA1c reduction
11,403 USD
basal insulin cohort
Source sentences
Summary
Diabetes-related costs per 1% reduction were numerically lower for the dulaglutide cohort, but the difference was not statistically significant ($9737 versus $11,403; p = 0.081).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational study used administrative claims data from the Optum Research Database.
Summary · context
Hispanic/Latino adults with T2D were assigned to dulaglutide or basal insulin cohorts on the basis of pharmacy claims and were propensity-score matched on demographic and baseline characteristics.
Report a problemFND-3842716409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.